NEW YORK (GenomeWeb) – BG Medicine has entered in financing agreements for $2.5 million, the company disclosed in a document filed with the US Securities and Exchange Commission on Tuesday.

The firm entered into a securities purchase agreement with its principal shareholders Applied Genomic Technology Capital Fund, AGTC Advisors Fund, and Flagship Ventures Fund, under which BG Medicine sold secured convertible promissory notes totaling $500,000. 

Additionally, BG Medicine has agreed to sell to the purchasers $2 million of newly created Series A preferred stock. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.